Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29694283.
- Also identified by DOI 10.18553/jmcp.2018.24.5.487 and PMC identifier 10398024.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Janssen, Millennium Pharmaceuticals, and Onyx Pharmaceuticals; and is a member of advisory boards for Amgen, Bristol-Myers Squibb, Celgene Corporation, Incyte, Kite, Legend Biotech, Sanofi-Aventis, and Takeda Pharmaceuticals.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Drug Resistance, Neoplasm
- Multiple Myeloma
- Neoplasm Recurrence, Local
- Patient Preference